Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

NCT00880282 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

NIH

Sponsor class

Conditions

Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL: cixutumumab
DRUG: temsirolimus
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)